Investigation Report on China Glipizide Market, 2010-2019
According to the statistics of International Diabetes Federation (IDF), in 2013, the prevalence of diabetes among adults aged from 20 to 79 was 8.3% and the number of diabetes patients has reached 382 million in the world, 80% of which come from middle income and low income countries and the figure demonstrates a fast rising trend. It is estimated that by 2035, there will be nearly 592 million people suffering from diabetes in the whole world. The number of diabetes patients in China was estimated to be 98.4 million in 2013, ranking first in the world, followed by India (65.1 million), USA (24.4 million), Brazil (11.9 million) and Russia (10.9 million). IDF estimates that by 2035, the number of diabetes patients in China will reach 143 million, still ranking first in the world while that in America will reach 29.7 million. The fast growth of diabetes in China and other developing countries has put a heavy burden on their social and economic development.
As one of the earliest oral antidiabetic drugs, sulfonylurea is common to patients with insulin hyposecretion. By stimulating insulin secretion, sulfonylurea is able to reduce blood glucose. According to the length of action, sulfonylurea can be categorized into short-acting, medium-acting and long-acting preparations. And glibenclamide, gliquidone, glipizide and glimepiride are the common drugs in the class of sulfonylurea.
As the first-line drug for type 2 diabetes, glipizide belongs to the second generation of sulfonylurea and it works by stimulating insulin secretion. Developed by Pfizer, glipizide was approved by FDA to enter the market in Apr. 1994. Glipizide in the Chinese market mainly comes from Pfizer (Trade Name: Glucotrol Common Name: Glipizide Controlled Release Tablets), Disha Pharmaceutical Group (Trade Name: Dishapian Common Name: Glipizide Tablets) and Yangtze River Pharmaceutical Group (Trade Name: Qinsu Common Name: Glipizide Extended Release Tablets). Although quite a lot local enterprises produce gliclazide, they all took up a small market share.
According to CRI’s market survey, in 2014, Pfizer (US) took up a market share of about 86% for sales value in China while other companies like Shandong Wanjie High-tech Co., Ltd, Yangtze River Pharmaceutical Group and Disha Pharmaceutical Group shared the rest market share. The annual sales value of glipizide stays at CNY 50-60 million during the period of 2005-2014.
The market size of glipizide is expected to stay at a certain level in the next few years in China.
Readers can get at least the following information through this report:
market size of glipizide in China
major manufacturers of glipizide for Chinese market and their market share
retail price of glipizide in Chinese market
market outlook of glipizide in China
The author suggests the following groups of people purchase this report:
manufacturers of anti-diabetic drugs
investors/ research institutions interested in Chinese medicine market
any interest in the medicine market, please contact CRI for customized survey service
Please Note: All reports from China Research and Intelligence are written in Chinese, then translated to English. This process takes approximately 5 business days from the date the order is placed